The ARHGEF6 Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the human ARHGEF6 gene has been disrupted to create a loss-of-function model. These polyclonal cells are derived from the Jurkat T lymphocyte line and offer a heterogeneous knockout pool, eliminating the need for single-cell cloning while providing a robust system for studying ARHGEF6-dependent signaling events. The product is supplied as a live cell population, expanded from a polyclonal pool after nuclease-mediated gene targeting, and is suitable for a wide range of downstream functional assays. This polyclonal knockout format captures the full spectrum of gene-editing outcomes across the cell population, enabling researchers to assess overall gene-function relationships without clonal bias.
Jurkat cells are an immortalized human T lymphocyte line originally isolated from a patient with acute T cell leukemia. This cell line is a widely accepted model for T cell receptor (TCR) signaling, immune activation, and T cell function. Jurkat cells express functional TCR complexes and key signaling intermediates, making them particularly valuable for dissecting pathways that regulate immune responses, integrin-mediated adhesion, and cytoskeletal dynamics. Their leukemic origin also provides relevance to cancer cell biology, especially in studies of hematopoietic malignancies and aberrant signaling networks. The polyclonal knockout of ARHGEF6 in this background permits the examination of gene function specifically within the context of T lymphocyte biology, without interference from clonal variation.
ARHGEF6, also known as ??-PIX, is a guanine nucleotide exchange factor (GEF) that specifically activates the small Rho GTPases RAC1 and CDC42 by catalyzing GDP/GTP exchange. Once activated, these GTPases stimulate downstream effectors including the p21-activated kinases PAK1 and PAK2, which in turn phosphorylate LIM kinases (LIMK1/2). Activated LIMK phosphorylates and inactivates cofilin, leading to actin polymerization and cytoskeletal reorganization. ARHGEF6 functions within a multiprotein complex that includes PAK1, GIT1, and ARHGEF7, and is itself regulated by signals from receptor tyrosine kinases, integrins, chemokine receptors, and growth factors. Through this cascade, ARHGEF6 controls actin dynamics, focal adhesion turnover, cell shape, and migration. The mechanistic pathway??ARHGEF6??RAC1/CDC42??PAK??LIMK??cofilin??actin??underlies processes such as immune synapse formation, T cell polarization, and invasive motility.
In Jurkat T cells, ARHGEF6 plays a central role in coupling TCR engagement to cytoskeletal changes required for effective immune response. Disruption of ARHGEF6 in this model permits direct interrogation of its function in T cell activation, spreading, migration, and adhesion, all processes that are dependent on RAC1- and CDC42-mediated actin remodeling. This knockout cell population is highly relevant for investigating the molecular basis of immune disorders, as well as the pathology of X-linked intellectual disability, where ARHGEF6 mutations are implicated. Additionally, since Jurkat cells exhibit oncogenic properties, the model provides a platform to study how Rho GTPase signaling contributes to cancer cell invasion and metastasis, linking ARHGEF6 activity to both normal immune function and malignant transformation.
Researchers can use these ARHGEF6 knockout polyclonal cells to explore Rho GTPase signaling in T lymphocytes, employing assays such as RAC1 activation G-LISA, western blotting for phospho-PAK, and transwell migration experiments. The absence of functional ARHGEF6 enables assessment of actin cytoskeletal defects through F-actin staining and immunofluorescence for focal adhesion markers like paxillin. The model is particularly suited for comparative studies with wild-type Jurkat cells to discern ARHGEF6-dependent pathways in immune synapse assembly, chemokine-directed migration, and integrin-mediated adhesion. It also serves as a valuable tool in drug discovery for screening compounds that modulate PAK or LIMK activity, or for validating targets in neurodevelopmental disorder research. For further technical details, please contact Ascent Research.
